CG Oncology, Inc. Diluted Shares Outstanding (Weighted Average)
CG Oncology, Inc. (CGON) reported Diluted Shares Outstanding (Weighted Average) of 88.20 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 88.20M shares, a 15.71% increase year-over-year.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 84.52M shares, a 10.93% increase year-over-year.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 80.06M shares, a 15.94% increase year-over-year.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 76.73M shares, a 14.28% increase year-over-year.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 77.30M shares, a 23.69% increase from fiscal 2024.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 62.50M shares, a 1343.03% increase from fiscal 2023.
- CG Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 4.33M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 88.20M shares 10-Q · filed 2026-08-06 | 86.37M shares 10-Q · filed 2026-08-06 | 84.26M shares derived: average of 3 quarters · filed 2026-08-06 | 82.38M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 84.52M shares 10-Q · filed 2026-05-08 | 82.29M shares derived: average of 2 quarters · filed 2026-05-08 | 80.44M shares derived: average of 3 quarters · filed 2026-05-08 | 79.38M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 80.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 78.40M shares derived: average of 2 quarters · filed 2026-02-27 | 77.67M shares derived: average of 3 quarters · filed 2026-08-06 | 77.30M shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 76.73M shares 10-Q · filed 2025-11-14 | 76.48M shares derived: average of 2 quarters · filed 2026-08-06 | 76.38M shares 10-Q · filed 2025-11-14 | 74.55M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 76.23M shares 10-Q · filed 2026-08-06 | 76.21M shares 10-Q · filed 2026-08-06 | 73.82M shares derived: average of 3 quarters · filed 2026-08-06 | 72.15M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 76.19M shares 10-Q · filed 2026-05-08 | 72.62M shares derived: average of 2 quarters · filed 2026-05-08 | 70.80M shares derived: average of 3 quarters · filed 2026-05-08 | 69.76M shares derived: average of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | 69.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 68.10M shares derived: average of 2 quarters · filed 2026-02-27 | 67.62M shares derived: average of 3 quarters · filed 2026-02-27 | 62.50M shares 10-K · filed 2026-02-27 |
| 2024-09-30 | 67.14M shares 10-Q · filed 2025-11-14 | 66.90M shares derived: average of 2 quarters · filed 2025-11-14 | 60.31M shares 10-Q · filed 2025-11-14 | 46.51M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | 66.65M shares 10-Q · filed 2025-08-08 | 56.86M shares 10-Q · filed 2025-08-08 | 39.63M shares derived: average of 3 quarters · filed 2026-02-27 | 30.82M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | 47.06M shares 10-Q · filed 2025-05-13 | 26.11M shares derived: average of 2 quarters · filed 2026-02-27 | 18.87M shares derived: average of 3 quarters · filed 2026-02-27 | 15.13M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | 5.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 4.77M shares derived: average of 2 quarters · filed 2026-02-27 | 4.49M shares derived: average of 3 quarters · filed 2026-02-27 | 4.33M shares 10-K · filed 2026-02-27 |
| 2023-09-30 | 4.38M shares 10-Q · filed 2024-11-12 | 4.15M shares derived: average of 2 quarters · filed 2024-11-12 | 4.05M shares 10-Q · filed 2024-11-12 | |
| 2023-06-30 | 3.92M shares 10-Q · filed 2024-08-08 | 3.89M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 3.86M shares 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |